• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Efficacy and safety of, and patient satisfaction with, colonoscopic-administered fecal microbiota transplantation in relapsing and refractory community- and hospital-acquired Clostridium difficile infection.结肠镜下粪菌移植治疗复发和难治性社区获得性及医院获得性艰难梭菌感染的疗效、安全性和患者满意度。
Can J Gastroenterol Hepatol. 2014 Sep;28(8):434-8. doi: 10.1155/2014/695029. Epub 2014 Jul 11.
2
Effect of Fecal Microbiota Transplantation on Recurrence in Multiply Recurrent Clostridium difficile Infection: A Randomized Trial.粪便微生物群移植对多次复发性艰难梭菌感染复发的影响:一项随机试验
Ann Intern Med. 2016 Nov 1;165(9):609-616. doi: 10.7326/M16-0271. Epub 2016 Aug 23.
3
Fecal microbiota transplant for relapsing Clostridium difficile infection using a frozen inoculum from unrelated donors: a randomized, open-label, controlled pilot study.使用来自非亲属供体的冷冻接种物进行粪便微生物群移植治疗复发性艰难梭菌感染:一项随机、开放标签、对照的试点研究。
Clin Infect Dis. 2014 Jun;58(11):1515-22. doi: 10.1093/cid/ciu135. Epub 2014 Apr 23.
4
The outcome and long-term follow-up of 94 patients with recurrent and refractory Clostridium difficile infection using single to multiple fecal microbiota transplantation via retention enema.94例复发性和难治性艰难梭菌感染患者采用保留灌肠单次至多次粪便微生物群移植的结果及长期随访
Eur J Clin Microbiol Infect Dis. 2014 Aug;33(8):1425-8. doi: 10.1007/s10096-014-2088-9. Epub 2014 Mar 14.
5
Long-term Follow-up Study of Fecal Microbiota Transplantation for Severe and/or Complicated Clostridium difficile Infection: A Multicenter Experience.粪便微生物群移植治疗严重和/或复杂性艰难梭菌感染的长期随访研究:一项多中心经验
J Clin Gastroenterol. 2016 May-Jun;50(5):398-402. doi: 10.1097/MCG.0000000000000374.
6
Successful therapy of Clostridium difficile infection with fecal microbiota transplantation.粪便微生物群移植成功治疗艰难梭菌感染
J Physiol Pharmacol. 2016 Dec;67(6):859-866.
7
Fecal microbiota transplantation for relapsing Clostridium difficile infection in 26 patients: methodology and results.26 例复发性艰难梭菌感染患者的粪便微生物群移植:方法和结果。
J Clin Gastroenterol. 2012 Feb;46(2):145-9. doi: 10.1097/MCG.0b013e318234570b.
8
Faecal microbiota transplantation for treatment of recurrent or refractory infection in Hong Kong.粪便微生物群移植治疗香港复发性或难治性感染。
Hong Kong Med J. 2019 Jun;25(3):178-182. doi: 10.12809/hkmj197855. Epub 2019 May 29.
9
[Fecal microbiota transplantation through colonoscopy for Clostridium difficile recurrent infection. Report of eight cases].[结肠镜检查下粪菌移植治疗艰难梭菌复发性感染:8例报告]
Rev Med Chil. 2018 Aug;146(8):823-830. doi: 10.4067/s0034-98872018000800823.
10
Initial experience with fecal microbiota transplantation in Clostridium difficile infection - transplant protocol and preliminary results.艰难梭菌感染粪便微生物群移植的初步经验——移植方案及初步结果
Rev Esp Enferm Dig. 2015 Jul;107(7):402-7. doi: 10.17235/reed.2015.3767/2015.

引用本文的文献

1
Clinical Practice Guidelines for Fecal Microbiota Transplantation in Korea.韩国粪便微生物群移植临床实践指南。
J Neurogastroenterol Motil. 2022 Jan 30;28(1):28-42. doi: 10.5056/jnm21221.
2
Adverse events of fecal microbiota transplantation: a meta-analysis of high-quality studies.粪便微生物群移植的不良事件:高质量研究的荟萃分析。
Ann Gastroenterol. 2021 Nov-Dec;34(6):802-814. doi: 10.20524/aog.2021.0655. Epub 2021 Jul 2.
3
Safety of fecal microbiota transplantation for infection focusing on pathobionts and SARS-CoV-2.粪便微生物群移植治疗感染的安全性,重点关注致病共生菌和严重急性呼吸综合征冠状病毒2
Therap Adv Gastroenterol. 2021 Apr 21;14:17562848211009694. doi: 10.1177/17562848211009694. eCollection 2021.
4
Faecal microbiota transplantation for recurrent infection: An updated systematic review and meta-analysis.粪便微生物群移植治疗复发性感染:一项更新的系统评价和荟萃分析。
EClinicalMedicine. 2020 Nov 23;29-30:100642. doi: 10.1016/j.eclinm.2020.100642. eCollection 2020 Dec.
5
Efficacy of different faecal microbiota transplantation protocols for infection: A systematic review and meta-analysis.不同粪便微生物群移植方案治疗感染的疗效:一项系统评价和荟萃分析。
United European Gastroenterol J. 2018 Oct;6(8):1232-1244. doi: 10.1177/2050640618780762. Epub 2018 Jun 3.
6
Cost-Effectiveness Analysis of Five Competing Strategies for the Management of Multiple Recurrent Community-Onset Clostridium difficile Infection in France.法国复发性社区获得性艰难梭菌感染多种竞争策略管理的成本效益分析
PLoS One. 2017 Jan 19;12(1):e0170258. doi: 10.1371/journal.pone.0170258. eCollection 2017.
7
Fecal Microbiota Therapy for Clostridium difficile Infection: A Health Technology Assessment.艰难梭菌感染的粪便微生物群疗法:一项卫生技术评估。
Ont Health Technol Assess Ser. 2016 Jul 1;16(17):1-69. eCollection 2016.
8
GUT in FOCUS Symposium NOBEL FORUM, Karolinska Institutet, February 2nd 2015.聚焦肠道研讨会 诺贝尔论坛,卡罗琳学院,2015年2月2日
Microb Ecol Health Dis. 2015 May 29;26:28480. doi: 10.3402/mehd.v26.28480. eCollection 2015.
9
Feces transplantation for recurrent Clostridium difficile infection: US experience and recommendations.粪菌移植治疗复发性艰难梭菌感染:美国的经验与建议
Microb Ecol Health Dis. 2015 May 29;26:27657. doi: 10.3402/mehd.v26.27657. eCollection 2015.
10
Hospitalization Type and Subsequent Severe Sepsis.住院类型与随后的严重脓毒症
Am J Respir Crit Care Med. 2015 Sep 1;192(5):581-8. doi: 10.1164/rccm.201503-0483OC.

本文引用的文献

1
Duodenal infusion of donor feces for recurrent Clostridium difficile.经十二指肠输注供体粪便治疗复发性艰难梭菌感染。
N Engl J Med. 2013 Jan 31;368(5):407-15. doi: 10.1056/NEJMoa1205037. Epub 2013 Jan 16.
2
Relationship of symptom duration and fecal bacteriotherapy in Clostridium difficile infection-pooled data analysis and a systematic review.艰难梭菌感染中症状持续时间与粪便细菌疗法的关系——汇总数据分析与系统评价
Scand J Gastroenterol. 2013 Mar;48(3):266-73. doi: 10.3109/00365521.2012.743585. Epub 2012 Nov 19.
3
Outcomes in community-acquired Clostridium difficile infection.社区获得性艰难梭菌感染的结局。
Aliment Pharmacol Ther. 2012 Mar;35(5):613-8. doi: 10.1111/j.1365-2036.2011.04984.x. Epub 2012 Jan 10.
4
Editorial: not so nosocomial anymore: the growing threat of community-acquired Clostridium difficile.社论:不再是医院内感染:越来越多的社区获得性艰难梭菌的威胁。
Am J Gastroenterol. 2012 Jan;107(1):96-8. doi: 10.1038/ajg.2011.404.
5
The epidemiology of community-acquired Clostridium difficile infection: a population-based study.社区获得性艰难梭菌感染的流行病学:一项基于人群的研究。
Am J Gastroenterol. 2012 Jan;107(1):89-95. doi: 10.1038/ajg.2011.398. Epub 2011 Nov 22.
6
Prevalence and diversity of Clostridium difficile strains in infants.婴儿艰难梭菌菌株的流行率和多样性。
J Med Microbiol. 2011 Aug;60(Pt 8):1112-1118. doi: 10.1099/jmm.0.029736-0. Epub 2011 Mar 10.
7
Fidaxomicin versus vancomycin for Clostridium difficile infection. fidaxomicin 与万古霉素治疗艰难梭菌感染。
N Engl J Med. 2011 Feb 3;364(5):422-31. doi: 10.1056/NEJMoa0910812.
8
Treatment of Clostridium difficile-associated disease.艰难梭菌相关性疾病的治疗
Gastroenterology. 2009 May;136(6):1899-912. doi: 10.1053/j.gastro.2008.12.070. Epub 2009 May 7.
9
A case-control study of community-associated Clostridium difficile infection.一项关于社区相关性艰难梭菌感染的病例对照研究。
J Antimicrob Chemother. 2008 Aug;62(2):388-96. doi: 10.1093/jac/dkn163. Epub 2008 Apr 22.
10
Recommendations for surveillance of Clostridium difficile-associated disease.艰难梭菌相关性疾病监测建议。
Infect Control Hosp Epidemiol. 2007 Feb;28(2):140-5. doi: 10.1086/511798. Epub 2007 Jan 25.

结肠镜下粪菌移植治疗复发和难治性社区获得性及医院获得性艰难梭菌感染的疗效、安全性和患者满意度。

Efficacy and safety of, and patient satisfaction with, colonoscopic-administered fecal microbiota transplantation in relapsing and refractory community- and hospital-acquired Clostridium difficile infection.

出版信息

Can J Gastroenterol Hepatol. 2014 Sep;28(8):434-8. doi: 10.1155/2014/695029. Epub 2014 Jul 11.

DOI:10.1155/2014/695029
PMID:25014180
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4210234/
Abstract

OBJECTIVE

To report the efficacy and safety of, and patient satisfaction with, colonoscopic fecal microbiota transplantation (FMT) for community- and hospital-acquired Clostridium difficile infection (CDI).

METHODS

A retrospective medical records review of patients who underwent FMT between July 1, 2012 and August 31, 2013 was conducted. A total of 22 FMTs were performed on 20 patients via colonoscopy. The patients were divided into 'community-acquired' and 'hospital-acquired' CDI. Telephone surveys were conducted to determine procedure outcome and patient satisfaction. Primary cure rate was defined as resolution of diarrhea without recurrence within three months of FMT, whereas secondary cure rate described patients who experienced resolution of diarrhea and return of normal bowel function after a second course of FMT.

RESULTS

Nine patients met the criteria for community-acquired CDI whereas 11 were categorized as hospital-acquired CDI. A female predominance in the community-acquired group (88.89% [eight of nine]) was found (P=0.048). The primary cure rate was 100% (nine of nine) and 81.8% (nine of 11 patients) in community- and hospital-acquired CDI groups, respectively (P=0.189). Two patients in the hospital-acquired group had to undergo a repeat FMT for persistent symptomatic infection; the secondary cure rate was 100%. During the six-month follow-up, all patients were extremely satisfied with the procedure and no complications or adverse events were reported.

CONCLUSION

FMT was a highly successful and very acceptable treatment modality for treating both community- and hospital-acquired CDI.

摘要

目的

报告经结肠镜进行粪便微生物群移植(FMT)治疗社区获得性和医院获得性艰难梭菌感染(CDI)的疗效、安全性和患者满意度。

方法

对 2012 年 7 月 1 日至 2013 年 8 月 31 日期间接受 FMT 的患者进行回顾性病历审查。共对 20 例患者进行了 22 例 FMT,均通过结肠镜进行。将患者分为“社区获得性”和“医院获得性”CDI。通过电话调查确定手术结果和患者满意度。主要治愈率定义为 FMT 后三个月内腹泻缓解且无复发,而二次治愈率描述的是在接受第二次 FMT 后腹泻缓解且肠道功能恢复正常的患者。

结果

9 例患者符合社区获得性 CDI 的标准,11 例患者归类为医院获得性 CDI。社区获得性组中女性占主导地位(88.89%[9 例中的 8 例])(P=0.048)。社区获得性和医院获得性 CDI 组的主要治愈率分别为 100%(9 例中的 9 例)和 81.8%(11 例中的 9 例)(P=0.189)。医院获得性组中有 2 例患者因持续性症状性感染需要重复 FMT,二次治愈率为 100%。在 6 个月的随访中,所有患者对该手术非常满意,且无并发症或不良事件报告。

结论

FMT 是治疗社区获得性和医院获得性 CDI 的一种非常成功且非常可接受的治疗方法。